Targeted inhibition plus immune checkpoint blockade: The new frontier for KRAS-mutant cancers

(1:31)

Targeted Inhibition of Signal Molecules as Novel Therapy For CLL

(20:59)

Targeted covalent inhibitors with an emphasis on reversible covalent inhibition

(42:)

Katherine Donovan - Dana-Farber Targeted Degradation Webinar Series

(55:)

Targeting Inhibitor of Apoptosis Proteins for Cancer Therapy: A Double-Edge Sword?

(1:29)

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

(7:51)

Targeted Therapy-BRAF Inhibitors and Beyond

(16:59)

Pharmacology - CANCER DRUGS – CELL CYCLE INHIBITORS (MADE EASY)

(13:36)

Drugging the Undruggable Cancer Targets

(46:37)

Targeted Inhibition of WRN Helicase, Replication Stress, and Cancer

(10:51)

AKT inhibitors: a new type of targeted cancer drug

(2:15)

Mechanisms of PARP Inhibition: A Mode of Targeted Cancer Treatment

(5:19)

Optimizing GBM tumor targeting through radiotherapy and DNA repair inhibition

(3:48)

Cancer Immune Checkpoint Inhibitors

(5:33)

Introduction to EGFR inhibitors

(5:32)

Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma

(1:41)

Targeting the immune system with checkpoint inhibitors

(27:43)

EPZ-6438: Targeted Therapy for Cancer via EZH2 Inhibition | GlpBio

(1:19)

Telomerase inhibition as a novel targeted therapy for myelofibrosis

(1:19)

Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?

(3:8)